Morgan Stanley Lowers Baxter International (NYSE:BAX) Price Target to $15.00

Baxter International (NYSE:BAX) had its price target reduced by Morgan Stanley from $19.00 to $15.00 in a research report issued on Tuesday, MarketBeat Ratings reports. The firm presently has an “underweight” rating on the medical instruments supplier’s stock. Morgan Stanley’s price target points to a potential downside of 20.50% from the stock’s current price.

BAX has been the subject of several other reports. Citigroup cut their price objective on Baxter International from $26.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, October 31st. Barclays cut their price target on shares of Baxter International from $41.00 to $36.00 and set an “overweight” rating on the stock in a report on Monday, August 4th. Evercore ISI decreased their price objective on shares of Baxter International from $31.00 to $24.00 in a research note on Thursday, October 30th. Cowen reissued a “hold” rating on shares of Baxter International in a research report on Thursday, October 30th. Finally, Stifel Nicolaus reduced their target price on shares of Baxter International from $25.00 to $22.00 in a report on Friday, October 31st. Two analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Baxter International currently has an average rating of “Hold” and a consensus target price of $22.50.

Baxter International Stock Performance

Shares of BAX stock opened at $18.87 on Tuesday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.18 and a current ratio of 1.84. The firm has a market capitalization of $9.70 billion, a price-to-earnings ratio of -28.59, a price-to-earnings-growth ratio of 1.09 and a beta of 0.61. Baxter International has a one year low of $17.40 and a one year high of $37.74. The company has a 50 day moving average price of $20.57 and a 200 day moving average price of $24.93.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.09. The company had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.88 billion. Baxter International had a negative net margin of 3.09% and a positive return on equity of 17.38%. Baxter International’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the business earned $0.80 EPS. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS and its FY 2025 guidance at 2.350-2.400 EPS. Sell-side analysts anticipate that Baxter International will post 2.48 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Zions Bancorporation National Association UT purchased a new stake in Baxter International during the 1st quarter worth approximately $27,000. CoreFirst Bank & Trust bought a new stake in shares of Baxter International in the second quarter worth $27,000. Creative Financial Designs Inc. ADV increased its stake in shares of Baxter International by 169.6% in the second quarter. Creative Financial Designs Inc. ADV now owns 984 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 619 shares during the last quarter. MTM Investment Management LLC acquired a new stake in Baxter International in the second quarter valued at $30,000. Finally, Imprint Wealth LLC bought a new position in Baxter International during the 3rd quarter valued at $27,000. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.